Sugi Predict

Sugi Predict / Compounds / SCHEMBL2174007

SCHEMBL2174007

SCHEMBL2174007

COC(=O)c1ccc(C=O)n1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ MAPK1 P28482 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ GAA P10253 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ HDAC10 Q969S8 1/20 0.40
▸ HDAC3 O15379 1/20 0.38
▸ HDAC4 P56524 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC7 Q8WUI4 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ HDAC9 Q9UKV0 1/20 0.38
▸ HDAC5 Q9UQL6 1/20 0.38
▸ TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL69407 0.82 KDM4E (0.53) NPC1KDM4ENPSR1ALDH1A1MAPK1
SCHEMBL10681112 0.81 LMNA (0.44) NPC1KDM4ENPSR1ALDH1A1SMN1; SMN2
SCHEMBL3494614 0.79 HDAC10 (0.40) KDM4EALDH1A1ATML3MBTL1GAA
SCHEMBL3494502 0.76 HPGD (0.47) KDM4EALDH1A1MAPK1L3MBTL1RAB9A
SCHEMBL2707500 0.75 TDP1 (0.49) NPC1ALDH1A1MAPK1L3MBTL1SMN1; SMN2
SCHEMBL7860405 0.75 NPC1 (0.47) NPC1KDM4ENPSR1ALDH1A1MAPK1
SCHEMBL12748885 0.75 NPC1 (0.47) NPC1KDM4ENPSR1ALDH1A1MAPK1
SCHEMBL13804468 0.75 NPC1 (0.47) NPC1KDM4ENPSR1ALDH1A1MAPK1
SCHEMBL1422582 0.74 ALDH1A1 (0.36) KDM4EALDH1A1MAPK1GAATSHR
SCHEMBL21448919 0.73 NPC1 (0.46) NPC1KDM4ENPSR1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119977956-A 3, 5-Disubstituted-1, 2, 4-triazole compound and preparation method and application thereof 华东师范大学 2025-05-13 — — CN disclosed
WO-2024155555-A1 NEUROPROTECTIVE COMPOUNDS FOR THERAPEUTIC USE NIMML INSTITUTE (US) 2024-07-25 — — WO disclosed
EP-3440073-B1 KINASE INHIBITORS OXULAR ACQUISITIONS LTD (GB) 2022-06-08 — — EP disclosed
CN-109071505-B Kinase inhibitors 奥苏拉收购有限公司 2021-11-16 — — CN disclosed
US-10442828-B2 Kinase inhibitors TOPIVERT PHARMA LIMITED (GB) 2019-10-15 — — US disclosed
EP-3440073-A1 KINASE INHIBITORS Topivert Pharma Limited (GB) 2019-02-13 — — EP disclosed
US-20180305383-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2018-10-25 — — US disclosed
US-10072034-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2018-09-11 — — US disclosed
US-20170291917-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2017-10-12 — — US disclosed
WO-2017174995-A1 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2017-10-12 — — WO disclosed
WO-2014202580-A1 SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-12-24 — — WO disclosed
EP-2050446-B1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-05-07 — — EP disclosed
US-7973078-B2 Sulfonamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2011-07-05 — — US disclosed
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 — — US disclosed
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 — — US disclosed
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 — — US disclosed
WO-2010118208-A1 BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-10-14 — — WO disclosed
WO-2010118208-A1 BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-10-14 — — WO disclosed
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-12-17 — — US disclosed
EP-2050446-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2009-04-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072034-B2 Kinase inhibitors SYK, LYN, BTK NPC1 4825/4885KDM4E 2053/4885NPSR1 1649/4885
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using MTOR, RICTOR, RPTOR NPC1 181/4885KDM4E 718/4885NPSR1 2952/4885
US-20180305383-A1 KINASE INHIBITORS SYK, LTK, LTB4R NPC1 4645/4885KDM4E 2216/4885NPSR1 1074/4885
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF PTGER1, CYSLTR1, PTGER2 NPC1 2796/4885KDM4E 4231/4885NPSR1 32/4885
US-10442828-B2 Kinase inhibitors SYK, LTK, LTB4R NPC1 4645/4885KDM4E 2216/4885NPSR1 1074/4885
US-20170291917-A1 KINASE INHIBITORS SYK, LYN, BTK NPC1 4825/4885KDM4E 2053/4885NPSR1 1649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.